Last updated: April 25, 2026
What is the case and where did it land?
Intercept Pharmaceuticals, Inc. v. Lupin Limited is a federal patent dispute filed under the U.S. Hatch-Waxman framework and docketed as 1:20-cv-01155. The case tests patent coverage around Intercept’s marketed and development-stage GI/hepatology assets against Lupin’s proposed generic entry path.
Forum and parties
- Plaintiff: Intercept Pharmaceuticals, Inc.
- Defendant: Lupin Limited
- Case number: 1:20-cv-01155
- Court: U.S. federal district court (docketed as above)
What claims are typically at issue in this posture?
In Intercept v. Lupin cases, the asserted core is usually alignment with the ANDA paragraph IV structure: Intercept alleges Lupin’s ANDA filing infringes one or more Orange Book-listed patents for a specific Intercept product (typically a bile-acid or liver-targeted therapy), with infringement and invalidity issues framed through:
- Direct and/or indirect infringement of asserted claims
- Anticipation/obviousness defenses tied to prior art and the asserted patent’s validity
- Procedural defenses tied to Orange Book listing, patent eligibility, and ANDA compliance
- Remedies: permanent injunction and damages (depending on posture)
Which Intercept product(s) and patent type(s) are normally implicated?
Intercept’s litigation footprint against generics most often centers on farnesoid X receptor (FXR) pathway assets and liver-related indications, where patent families include:
- Composition-of-matter patents
- Method-of-use patents (often tied to indication or dosing regimens)
- Formulation or crystalline form patents (where relevant)
- Regulatory exclusivity leverage via listing and expiry windows
This docket number corresponds to Intercept’s federal enforcement against a Lupin generic filing in the same legal lane as its other ANDA-driven disputes.
What is the litigation timeline and procedural posture that drives exposure?
The business risk in ANDA litigation is usually driven by two event types:
- Claim construction and early motion practice (impacting which claims survive and whether a case pivots toward settlement)
- Injunction timing relative to the 180-day exclusivity window and generic launch schedules
For 1:20-cv-01155, the risk profile follows the typical Hatch-Waxman sequence:
- Filing of the suit after ANDA/paragraph IV certification
- Markman/claim construction shaping the infringement map
- Infringement and invalidity briefing tied to the asserted patent set
- Trial or settlement with potential consent judgment terms
What are the core infringement and validity theories?
Without reproducing court text not contained in the provided record, the legal architecture for this case type is as follows.
Infringement theories commonly asserted
Intercept generally frames infringement as:
- Lupin’s ANDA product will infringe by meeting the claimed composition and/or method parameters upon commercial manufacture and sale for the label use.
- If method claims are asserted, Intercept often argues that the proposed prescribing instructions and label alignment cause direct infringement by healthcare providers and indirect infringement by Lupin.
Validity theories commonly raised by Lupin
Lupin generally litigates:
- Invalidity under 35 U.S.C. §§ 102 and 103 using prior publications and patents
- Obviousness combinations tied to known FXR/liver therapy teachings
- Patent eligibility challenges where applicable to the asserted claim set
- Non-infringement based on proposed product differences or claim construction outcomes
What does the case do to Lupin’s launch economics?
In Hatch-Waxman disputes, the economic effect typically flows from:
- Whether an injunction issues preventing launch until patent expiry
- Whether the case narrows to fewer asserted patents or claims
- Whether a settlement agreement triggers early entry at risk or allows launch before the latest expiry date with design-around constraints
For a defendant, the levers are:
- Reducing exposure by invalidating the broadest claims (often composition and method cores)
- Engineering a non-infringing label or manufacturing profile
- Reaching a typical settlement structure that avoids a hard injunction while paying consideration, accepting entry timing, or both
What would an investor need to know to size upside/downside here?
The key risk sizing inputs in a case like this are:
- Number of asserted patents and their remaining term as of filing
- Which claim types survive early motions
- Whether the asserted patents include combination coverage (e.g., composition plus dosing regime) that makes design-around harder
- Likelihood of an injunction vs a damages-only outcome, which depends on claim strength and procedural status
This docket number is the anchor for those inputs, but the record provided here does not include the specific asserted patent list, claim numbers, or dates.
Litigation impact map: business questions the docket answers
Even without reproducing the full claim-by-claim record here, the docket’s business impact typically resolves into:
Does the docket support a sustained exclusivity barrier or a path to earlier entry?
- If multiple core claims remain intact, it supports a hard barrier to launch.
- If only narrow claims survive or invalidity is likely, it supports earlier generic entry.
Is there a settlement signal?
- Settlements in this lane often include entry timing tied to patent expiry or design-around allowances.
How much of Intercept’s IP portfolio is effectively “cleared” in this case?
- A strong ruling can reduce portfolio uncertainty.
- A narrow ruling can leave other patents to govern.
Key Takeaways
- 1:20-cv-01155 is an Intercept v. Lupin Hatch-Waxman patent dispute where the legal and commercial stakes turn on Orange Book-listed patent coverage and the ANDA paragraph IV challenge.
- The case’s economic driver is the standard Hatch-Waxman outcome set: injunction risk, claim survival through claim construction, and settlement or launch timing.
- The practical sizing inputs are the asserted patent set, remaining term at filing, and which claim types survive early motions. Those determine whether Lupin faces a launch block or a pathway to entry at reduced legal risk.
FAQs
What legal mechanism brought Intercept v. Lupin Limited (1:20-cv-01155)?
It is a federal patent infringement case tied to a Hatch-Waxman ANDA/paragraph IV-style challenge, where the plaintiff asserts that the defendant’s proposed generic infringes one or more Orange Book-listed patents.
What drives the potential injunction outcome in this case type?
Claim construction, infringement fit to the proposed product and label, and validity outcomes on the asserted patents determine whether a court issues a launch-blocking injunction or a damages-only outcome.
What claims usually matter most in Intercept’s generic challenges?
Composition-of-matter and method-of-use claims typically drive the highest barrier to entry because they are harder to design around without changing the product or label.
How does a settlement typically resolve Hatch-Waxman disputes like this?
Settlement terms typically allocate entry timing relative to patent expiry and may include design-around commitments and/or monetary consideration to avoid continued litigation and an injunction fight.
What is the investor-facing metric to track after filing?
The asserted patent count and expected rulings on claim construction and invalidity, because these forecast whether Lupin’s path to launch is blocked, delayed, narrowed, or cleared.
References
[1] Intercept Pharmaceuticals, Inc. v. Lupin Limited, 1:20-cv-01155 (docket).
